Survey and Research Archives | Page 2 of 14 | Be Korea-savvy

Archive by category Survey and Research

World Conference on Lung Cancer Monday Press Conference: Dangers of Smoking and Lung Cancer Intervention Research

World Conference on Lung Cancer Monday Press Conference: Dangers of Smoking and Lung Cancer Intervention Research

YOKOHAMA, Japan, Oct. 16 (Korea Bizwire) — At today’s press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), the world’s preeminent lung cancer researchers provided new insights on CT screening, smoking cessation and mesothelioma. The discussion focused in particular on the conference’s host country of [...]

World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines

World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines

YOKOHAMA, Japan, Oct. 15 (Korea Bizwire) — The first press briefing at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new awards and innovations that encourage and support the treatment of lung cancer and other thoracic malignancies; these include the recognition of outstanding care teams, [...]

First Quantitative M&A Brand Study of S&P Global 100 Shows 74 percent Rebrand Post-acquisition; Sector, Deal Size, and Appetite Key Factors

First Quantitative M&A Brand Study of S&P Global 100 Shows 74 percent Rebrand Post-acquisition; Sector, Deal Size, and Appetite Key Factors

NEW YORK, Oct. 10 (Korea Bizwire) — In 2015 and 2016, mergers and acquisitions accounted for more than $8 trillion of business value. But while extensive due diligence and planning is given to financials and other factors during the deal-making process, brand strategy considerations are often overlooked or only evaluated post-M&A. This is due, in [...]

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 3 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced positive top-line results from the Phase II [...]

Synergy Research Group Ranks BroadSoft as the Global Market Share Leader for Unified Communications as a Service (UCaaS) at 49%

Synergy Research Group Ranks BroadSoft as the Global Market Share Leader for Unified Communications as a Service (UCaaS) at 49%

GAITHERSBURG, Md., Oct. 2 (Korea Bizwire) — BroadSoft, Inc. (NASDAQ:BSFT), a global leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today announced that it retained its number-one position in UCaaS new line shipments, and grew its market share from 42.6% [...]

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 2 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the Company has accelerated the timelines [...]

Largest, Most Popular Business School Programs Worldwide See Application Growth While Smaller Programs Experience Declines

Largest, Most Popular Business School Programs Worldwide See Application Growth While Smaller Programs Experience Declines

RESTON, Va., Sept. 19 (Korea Bizwire) — Nearly 3 in 4 (73 percent) graduate business programs with 201 or more class seats report increased application volumes this year compared to 39 percent of the smallest programs (50 or fewer class seats), according to a new application trends survey from the Graduate Management Admission Council (GMAC). [...]

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit

SAN DIEGO, Aug. 1 (Korea Bizwire) — Invivoscribe® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine®, today announces the release of the CE-marked IVD version of its LeukoStrat® CDx FLT3 Mutation Assay which earlier this year was approved by [...]

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

TEL-AVIV, Israel and RALEIGH, N.C., Jul. 17 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the last patient enrolled in the [...]

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Jul. 12 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the second independent Data and [...]